ENTA - Enanta Pharmaceuticals Inc Stock Price, Fair Value and News

15.48USD+0.15 (+0.98%)Market Closed

Market Summary

USD15.48+0.15

Market Closed

0.98%

ENTA Stock Price

View Fullscreen

ENTA RSI Chart

ENTA Valuation

Market Cap

327.9M

Price/Earnings (Trailing)

-2.49

Price/Sales (Trailing)

4.5

EV/EBITDA

-2.28

Price/Free Cashflow

-2.89

ENTA Price/Sales (Trailing)

ENTA Profitability

EBT Margin

-178.25%

Return on Equity

-79.3%

Return on Assets

-31.85%

Free Cashflow Yield

-34.56%

ENTA Fundamentals

ENTA Revenue

Revenue (TTM)

72.9M

Rev. Growth (Yr)

-4.16%

Rev. Growth (Qtr)

-5.27%

ENTA Earnings

Earnings (TTM)

-131.7M

Earnings Growth (Yr)

17.26%

Earnings Growth (Qtr)

6.74%

Breaking Down ENTA Revenue

Last 7 days

4.2%

Last 30 days

25.1%

Last 90 days

23.9%

Trailing 12 Months

-18.6%

How does ENTA drawdown profile look like?

ENTA Financial Health

Current Ratio

6.43

ENTA Investor Care

Shares Dilution (1Y)

0.59%

Diluted EPS (TTM)

-6.24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	72.9M	0	0	0
2023	81.2M	80.6M	79.2M	73.6M
2022	91.6M	89.4M	86.2M	82.1M
2021	94.2M	97.1M	97.1M	93.0M
2020	175.9M	150.2M	122.5M	101.6M
2019	234.0M	221.1M	205.2M	187.9M
2018	165.6M	215.3M	206.6M	238.4M
2017	46.2M	39.7M	102.8M	130.5M
2016	87.5M	89.8M	88.3M	50.2M
2015	179.6M	149.1M	160.9M	131.8M
2014	6.1M	46.5M	47.7M	124.3M
2013	36.9M	34.5M	32.1M	5.1M
2012	0	0	41.7M	39.3M

Get all data in R, Python etc through our Historical Stock Data APIs

About Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

CEO	Dr. Jay R. Luly Ph.D.
WEBSITE	enanta.com
INDUSTRY	Biotechnology
EMPLOYEES	160

Enanta Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Enanta Pharmaceuticals Inc? What does ENTA stand for in stocks?

ENTA is the stock ticker symbol of Enanta Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Enanta Pharmaceuticals Inc (ENTA)?

As of Thu Jul 25 2024, market cap of Enanta Pharmaceuticals Inc is 324.68 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ENTA stock?

You can check ENTA's fair value in chart for subscribers.

Is Enanta Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ENTA is over valued or under valued. Whether Enanta Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Enanta Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ENTA.

What is Enanta Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, ENTA's PE ratio (Price to Earnings) is -2.46 and Price to Sales (PS) ratio is 4.45. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ENTA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Enanta Pharmaceuticals Inc's stock?

In the past 10 years, Enanta Pharmaceuticals Inc has provided -0.088 (multiply by 100 for percentage) rate of return.